Compare Immunovant Inc. Common Stock (IMVT) vs News Corporation Class A Common Stock (NWSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs News Corporation Class A Common Stock — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while News Corporation Class A Common Stock trades at $29.01 (market cap $15.95B). The key difference: News Corporation Class A Common Stock is far larger — about 2.4× Immunovant Inc. Common Stock's market cap, and News Corporation Class A Common Stock pays a 0.7% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and News Corporation Class A Common Stock for 0 Days on average.
| IMVT | NWSA | |
|---|---|---|
Market Cap | $6.62B | $15.95B |
Volume | 1,131,364 | 3,890,129 |
Sector | Health | Media |
52-Week High | $44.96 | $31.19 |
52-Week Low | $17.03 | $22.40 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $5.72B | $16.77B |
Dividend Yield | — | 0.7% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About News Corporation Class A Common Stock
News Corporation operates businesses in news and information services, digital real estate, and book publishing. Its brands include Dow Jones, The Wall Street Journal, HarperCollins, Realtor.com, and realestate.com.au.
Read more on NWSA →
